Site de l’association HerPAs

Publications scientifiques de 2011


Genotypic cha­rac­te­ri­za­tion of herpes sim­plex virus DNA poly­me­rase UL42 pro­ces­si­vity factor : HSV UL42 pro­ces­si­vity factor natu­ral poly­mor­phism. Sonia Burrel, Zaïna Aït Arkoub, Henri Agut, David Boutolleau. Antiviral Research, Available online 28 October 2011.

[Acute vari­cella zoster ence­pha­li­tis without evi­dence of pri­mary vas­cu­lo­pa­thy in a case-series of 20 patients]. De Broucker T, Mailles A, Chabrier S, Morand P, Stahl JP ; on behalf of the stee­ring com­mit­tee and inves­ti­ga­tors group. Clin Microbiol Infect. 2011 Oct 21. doi : 10.1111/j.1469-0691.2011.03705.x.

[Lymphohistiocytic acti­va­tion syn­drome and Burkholderia cepa­cia com­plex infec­tion in a child revea­ling chro­nic gra­nu­lo­ma­tous disease and chro­mo­so­mal inte­gra­tion of the HHV-6 genome]. Araujo A, Pagnier A, Frange P, Wroblewski I, Stasia MJ, Morand P, Plantaz D. Arch Pediatr. 2011 Apr ;18(4):416-9. French.

The Effect of HMGB1, a Damage-Associated Molecular Pattern Molecule, on Polymorphonuclear Neutrophil Migration Depends on Its Concentration. Berthelot F, Fattoum L, Casulli S, Gozlan J, Maréchal V, Elbim C. J Innate Immun. 2011 Aug 19.

[Occupational risk for cyto­me­ga­lo­vi­rus, but not for par­vo­vi­rus B19 in child-care per­son­nel in France]. de Villemeur AB, Gratacap-Cavallier B, Casey R, Baccard-Longère M, Goirand L, Seigneurin JM, Morand P. J Infect. 2011 Dec ;63(6):457-67.

Major source of anti­ge­nic pep­ti­des for the MHC class I path­way is pro­du­ced during the pio­neer round of mRNA trans­la­tion. Apcher S, Daskalogianni C, Lejeune F, Manoury B, Imhoos G, Heslop L, Fåhraeus R. Proc Natl Acad Sci U S A. 2011 Jul 12 ;108(28):11572-7.

Herpes sim­plex virus type 1-deri­ved recom­bi­nant and ampli­con vec­tors. Fraefel C, Marconi P, Epstein AL. Methods Mol Biol. 2011 ;737:303-43.

ICP27 pro­tein of Marek’s disease virus inte­racts with SR pro­teins and inhi­bits the spli­cing of cel­lu­lar telo­me­rase chTERT and viral vIL8 trans­cripts. Amor S, Strassheim S, Dambrine G, Remy S, Rasschaert D, Laurent S. J Gen Virol. 2011 Jun ;92(Pt 6):1273-8. Epub 2011 Feb 16.

Control of Plasmodium fal­ci­pa­rum ery­thro­cy­tic cycle : γδ T cells target the red blood cell-inva­sive mero­zoi­tes. Costa G, Loizon S, Guenot M, Mocan I, Halary F, de Saint-Basile G, Pitard V, Déchanet-Merville J, Moreau JF, Troye-Blomberg M, Mercereau-Puijalon O, Behr C. Blood. 2011 Dec 22 ;118(26):6952-62.

Pivotal advance : The pro­mo­tion of solu­ble DC-SIGN release by inflam­ma­tory signals and its enhan­ce­ment of cyto­me­ga­lo­vi­rus-media­ted cis-infec­tion of mye­loid den­dri­tic cells. Plazolles N, Humbert JM, Vachot L, Verrier B, Hocke C, Halary F. J Leukoc Biol. 2011 Mar ;89(3):329-42

Acute human her­pes­vi­rus 6 (HHV-6) infec­tions : when and how to treat ?. Agut H. Pathol Biol (Paris). 2011 Apr ;59(2):108-12.

The vari­cella-zoster virus ORF47 kinase inter­fe­res with host innate immune res­ponse by inhi­bi­ting the acti­va­tion of IRF3. Vandevenne P, Lebrun M, El Mjiyad N, Ote I, Di Valentin E, Habraken Y, Dortu E, Piette J, Sadzot-Delvaux C. PLoS One. 2011 Feb 9 ;6(2):e16870.

The Varicella-Zoster virus IE4 pro­tein : a conser­ved member of the her­pes­vi­ral mRNA export fac­tors family and a poten­tial alter­na­tive target in anti­her­pe­tic the­ra­pies. Ote I, Piette J, Sadzot-Delvaux C. Biochem Pharmacol. 2010 Dec 15 ;80(12):1973-80.

Deciphering the cli­ni­cal impact of acute human her­pes­vi­rus 6 (HHV-6) infec­tions. Agut H. J Clin Virol. 2011 Jul 20.

Genotypic cha­rac­te­ri­za­tion of human cyto­me­ga­lo­vi­rus UL97 phos­pho­trans­fe­rase natu­ral poly­mor­phism in the era of gan­ci­clo­vir and mari­ba­vir. Boutolleau D, Burrel S, Agut H. Antiviral Res. 2011 Jul ;91(1):32-5. doi : 10.1016/j.anti­vi­ral.2011.04.015.

Herpes sim­plex ence­pha­li­tis : from virus to the­rapy. Rozenberg F, Deback C, Agut H. Infect Disord Drug Targets. 2011 Jun 1 ;11(3):235-50.

NF-kappaB-media­ted modu­la­tion of indu­ci­ble nitric oxide syn­thase acti­vity controls induc­tion of the Epstein-Barr virus pro­duc­tive cycle by trans­for­ming growth factor beta 1. Oussaief L, Ramírez V, Hippocrate A, Arbach H, Cochet C, Proust A, Raphaël M, Khelifa R, Joab I. J Virol. 2011 Jul ;85(13):6502-12. Epub 2011 Apr 20.

Epstein-Barr virus latent mem­brane pro­tein 1 increa­ses cal­cium influx through store-ope­ra­ted chan­nels in B lym­phoid cells. Dellis O, Arbabian A, Papp B, Rowe M, Joab I, Chomienne C. J Biol Chem. 2011 May 27 ;286(21):18583-92. Epub 2011 Mar 30.

Possible role of EBV in breast cancer and other unu­sually EBV-asso­cia­ted can­cers. Hippocrate A, Oussaief L, Joab I. Cancer Lett. 2011 Jun 28 ;305(2):144-9.

Epidemiology of viral ence­pha­li­tis in 2011. Stahl JP, Mailles A, Dacheux L, Morand P. Med Mal Infect. 2011 Jul 28.

Lymphohistiocytic acti­va­tion syn­drome and Burkholderia cepa­cia com­plex infec­tion in a child revea­ling chro­nic gra­nu­lo­ma­tous disease and chro­mo­so­mal inte­gra­tion of the HHV-6 genome. Araujo A, Pagnier A, Frange P, Wroblewski I, Stasia MJ, Morand P, Plantaz D. Arch Pediatr. 2011 Apr ;18(4):416-9. French.

Detection of viral microRNA with S1 nuclease pro­tec­tion assay. John M, Pfeffer S. Methods Mol Biol. 2011 ;721:173-82

Novel model of pla­cen­tal tissue explants infec­ted by cyto­me­ga­lo­vi­rus reveals dif­fe­rent per­mis­si­ve­ness in early and term pla­cen­tae and inhi­bi­tion of indo­lea­mine 2,3-dioxy­ge­nase acti­vity. Lopez H, Benard M, Saint-Aubert E, Baron M, Martin H, Al Saati T, Plantavid M, Duga-Neulat I, Berrebi A, Cristini C, Arnaud C, Davrinche C, Davignon JL, Casper C. Placenta. 2011 Jul ;32(7):522-30. doi : 10.1016/j.pla­centa.2011.04.016.

Efficacy of L-aspa­ra­gi­nase with metho­trexate and dexa­me­tha­sone (AspaMetDex regi­men) in patients with refrac­tory or relap­sing extra­no­dal NK/T-cell lym­phoma, a phase 2 study. Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, Devidas A, Petit B, de Leval L, Gaulard P, Feuillard J, Bordessoule D, Hermine O ; GELA and GOELAMS Intergroup. Blood. 2011 Feb 10 ;117(6):1834-9.

Comparison of 2 highly auto­ma­ted nucleic acid extrac­tion sys­tems for quan­ti­ta­tion of human cyto­me­ga­lo­vi­rus in whole blood. Mengelle C, Mansuy JM, Da Silva I, Davrinche C, Izopet J. Diagn Microbiol Infect Dis. 2011 Feb ;69(2):161-6.

PCA-ELISA : a sen­si­tive method to quan­tify free and masked forms of HMGB1. Barnay-Verdier S, Gaillard C, Messmer M, Borde C, Gibot S, Maréchal V. Cytokine. 2011 Jul ;55(1):4-7.

Emergence of autoan­ti­bo­dies to HMGB1 is asso­cia­ted with sur­vi­val in patients with septic shock. Barnay-Verdier S, Fattoum L, Borde C, Kaveri S, Gibot S, Maréchal V. Intensive Care Med. 2011 Jun ;37(6):957-62.

Rapid obten­tion of stable, bio­lu­mi­nes­cent tumor cell lines using a tCD2-luci­fe­rase chi­me­ric cons­truct. Jimenez AS, Gressette M, Barjon C, Wei M, Gourzones C, Busson P. BMC Biotechnol. 2011 Mar 24 ;11:26.

Homozygous dele­tion of EPB41 genuine AUG-contai­ning exons results in mRNA spli­cing defects, NMD acti­va­tion and pro­tein 4.1R com­plete defi­ciency in here­di­tary ellip­to­cy­to­sis. Baklouti F, Morinière M, Haj-Khélil A, Fénéant-Thibault M, Gruffat H, Couté Y, Ninot A, Guitton C, Delaunay J. Blood Cells Mol Dis. 2011 Aug 10.

Advanced gly­ca­tion end pro­ducts inhi­bit both infec­tion and trans­mis­sion in trans of HIV-1 from mono­cyte-deri­ved den­dri­tic cells to auto­lo­gous T cells.Nasreddine N, Borde C, Gozlan J, Bélec L, Maréchal V, Hocini H. J Immunol. 2011 May 15 ;186(10):5687-95.

EBV lytic-phase pro­tein BGLF5 contri­bu­tes to TLR9 down­re­gu­la­tion during pro­duc­tive infec­tion.van Gent M, Griffin BD, Berkhoff EG, van Leeuwen D, Boer IG, Buisson M, Hartgers FC, Burmeister WP, Wiertz EJ, Ressing ME. J Immunol. 2011 Feb 1 ;186(3):1694-702.

Stepwise release of bio­lo­gi­cally active HMGB1 during HSV-2 infec­tion.Borde C, Barnay-Verdier S, Gaillard C, Hocini H, Maréchal V, Gozlan J. PLoS One. 2011 Jan 19 ;6(1):e16145.

The nuclear and adhe­rent junc­tion com­plex com­po­nent pro­tein ubi­nu­clein nega­ti­vely regu­la­tes the pro­duc­tive cycle of epstein-barr virus in epi­the­lial cells. Gruffat H, Lupo J, Morand P, Boyer V, Manet E. J Virol. 2011 Jan ;85(2):784-94.